Ratio of certain immune cells to tumor burden correlated with outcome for pembrolizumab-treated patients with melanoma
Among patients with stage IV melanoma who were being treated with the immunotherapeutic pembrolizumab (Keytruda), the ratio of a particular subset of immune cells in the blood to tumor burden correlated with clinical response, ...
Sep 27, 2016
0
0